HOME >> BIOLOGY >> NEWS
ENBREL rapidly, significantly improved back pain, mobility, function in ankylosing spondylitis

THOUSAND OAKS, Calif., and COLLEGEVILLE, Pa., June 19, 2003 - Amgen (NASDAQ: AMGN) and Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), today announced that patients in a phase 3 clinical study assessing the efficacy and tolerability of ENBREL. (etanercept) in the treatment of active ankylosing spondylitis experienced significant and rapid reduction in back pain and morning stiffness, and improvement in spinal mobility and physical function. The data are part of a presentation at the annual meeting of European League Against Rheumatism being held this week in Lisbon, Portugal.

"A significant number of patients treated with ENBREL in this study saw a marked improvement in as early as two weeks after initiation of treatment. Patients reached maximum relief within the first two months of the study and experienced sustained results for the remainder of the six-month study," said Dr. John Davis, assistant professor of medicine at the University of California-San Francisco and associate director of the Department of Medicine Clinical Trials Center. "I am excited about these encouraging results with ENBREL, especially since it is the first treatment to show improvement in AS patients' range of spinal motion in a phase 3 study."

The multi-center, double-blind, placebo-controlled study randomized 277 patients to receive either ENBREL (25 mg twice weekly; n=138) or placebo (n=139) over a 6-month period. The primary endpoint of the pivotal Phase 3 study was the percentage of patients at 12 weeks and 24 weeks achieving a 20 percent improvement in the Assessment in Ankylosing Spondylitis Response Criteria (ASAS 20), a composite measure that includes back pain, inflammation and physical function.

At week 12, 60 percent of patients treated with ENBREL achieved the ASAS 20 compared with 27 percent of patients in the placebo group. At 24 weeks, 58 percent of patients treated with ENBREL achieved the ASAS 20 compared with 23 percent of the placebo pati
'"/>

Contact: Rebecca Hamm, Amgen
805-447-3872
Porter Novelli
20-Jun-2003


Page: 1 2 3 4

Related biology news :

1. ENBREL provided rapid and significant relief for psoriasis patients in second pivotal study
2. Once weekly ENBREL significantly reduced rheumatoid arthritis pain, inflammation & improved function
3. ENBREL combo therapy inhibits joint damage progression, offers significant RA symptom relief
4. ENBREL is first therapy approved for psoriatic arthritis
5. New Phase 2 study shows ankylosing spondylitis patients respond to ENBREL (etanercept)
6. Phase 3 psoriatic arthritis data for ENBREL (etanercept) announced at a national scientific meeting
7. Rare mutations can significantly increase risk factor for heart disease
8. Cancer health risk significantly underestimated by EPAs ambient model estimates
9. Double mastectomies significantly lower risk of breast cancer in women who are genetically at risk
10. HAART therapy significantly prolongs survival in AIDS patients with central nervous system lymphoma
11. Cognitive abilities increase significantly with time in most prematurely born children

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/26/2017)... , Jan. 26, 2017  Crossmatch, a leading provider ... new solution aimed at combatting fraud, waste and abuse ... introduced at the Action on Disaster Relief conference in ... point for UN agencies and foreign assistance organizations throughout ... waste and abuse are a largely unacknowledged problem in ...
(Date:1/25/2017)... The Elements of Enterprise Information Security ... of a comprehensive set of business processes and ... identities and providing a secured and documented access ... number of programs opted by enterprises to maintain ... processes and changing policies. However, there are some ...
(Date:1/24/2017)... 24, 2017  It sounds simple and harmless—an ... monitors vital signs and alerts parents on their ... saturation level drops. But pediatric experts argue that ... with no evidence of medical benefits, especially to ... aggressively to parents of healthy babies, promising peace ...
Breaking Biology News(10 mins):
(Date:2/16/2017)...   Capricor Therapeutics, Inc. (NASDAQ: ... first-in-class biological therapies for cardiac and other medical ... terminate its license agreement with the Mayo Clinic ... "Our decision to return these rights ... efforts to advance our core cell and exosome-based ...
(Date:2/16/2017)...  Champions Oncology, Inc. (NASDAQ: CSBR ), ... advanced technology solutions and products to personalize the development ... of new cohorts of PDX models to their existing ... Champions, product line in hepatocellular cancer, breast cancer, castrate ... non-small cell lung cancer (including EGFR mutation; ALK/ROS1 positive) ...
(Date:2/16/2017)... ... February 16, 2017 , ... ... extended its industry leading Biochemistry Services specifically targeting the rapidly growing needs ... methods for the biochemical and biosimilar characterization , product-related impurity characterization, ...
(Date:2/15/2017)... Inc. (Vanda) (NASDAQ: VNDA), today announced financial and ... year ended December 31, 2016. "2016 ... continued to demonstrate strong growth in our commercial ... Mihael H. Polymeropoulos, M.D., Vanda,s President and CEO. ... milestones underscores Vanda,s commitment to bringing important new ...
Breaking Biology Technology:
Cached News: